BKHA — Black Hawk Acquisition Corp
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 2000775 ·
Last close
$8.65
Market Cap
$35.93M
52W High
$23.00
52W Low
$3.70
ADV30
137,762
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Aug 2026 | 0 | — | -138,210 | 1,074,736 | 26,034,667 | 12,052 | 4,750,491 |
| May 2026 | 0 | — | -109,215 | 88,929 | 25,376,246 | 11,583 | 5,166,806 |
| Feb 2026 | 0 | — | -54,189 | 139,805 | 24,821,943 | 178,407 | 4,701,432 |
| Nov 2025 | 0 | — | -217,878 | -3,765 | 23,877,939 | 39,521 | 3,897,233 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-725,232
Investing CF
$-1,350,000
Financing CF
$2,043,201
CapEx
—
Dividends Paid
—
Buybacks
$0
EPS Diluted TTM
$0.18
As of
2026-10-17
Balance + Analyst (yfinance extras)
Retained Earnings
$-5,108,417
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$2,835,748
Pretax Income TTM
$745,510
Interest Exp TTM
$43,830
Analysts
—
Annual Trend (SEC EDGAR, last 3y)
Revenues vs Net Income (last 3y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Nov 2025 | 0 | -915,510 | 1,329,557 | 23,877,939 | 3,897,233 | 19,980,706 | -650,321 |
| Nov 2024 | 0 | -576,076 | 1,915,703 | 72,143,335 | 2,485,978 | 69,657,357 | -553,665 |
| Nov 2023 | — | — | — | 263,000 | 256,853 | 6,147 | — |
TTM Snapshot
Revenues TTM
$922,632
NetIncome TTM
$379,370
OpCashFlow TTM
—
Assets (Latest)
$25,376,246
Forward EPS
—
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| TIL | Instil Bio, Inc. | $36.62M | $5.40 | — |
| CRBU | Caribou Biosciences, Inc. | $36.81M | $0.34 | — |
| TVGN | Tevogen Inc. | $37.05M | $5.69 | — |
| ELUT | ELUTIA INC. | $37.91M | $0.85 | — |
| KLRS | Kalaris Therapeutics, Inc. | $34.04M | $1.43 | — |
News headlines (Yahoo Finance, 1h cache)
Black Hawk Acquisition Corporation Announces Redemption Results in Connection With Its Business Combination With Vesicor Therapeutics Inc.
2026-10-14 10:00 · Yahoo
Vesicor Therapeutics Appoints Michael Tolentino, M.D., as Chief Executive Officer
2026-03-19 02:42 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.